LMLinda H. Malkas

Linda H. Malkas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Linda H. Malkas has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Robert J. Hickey

    Department of Molecular Medicine, City of Hope National Medical Center, Duarte, USA

    6 shared publications
  • Robert J. Hickey

    Beckman Research Institute of City of Hope 7 Duarte, CA

    5 shared publications
  • J. Jefferson P. Perry

    Department of Molecular Diagnostics & Experimental Therapeutics, Beckman Research Institute of City of Hope, Duarte, USA

    3 shared publications
  • Jennifer Jossart

    Department of Molecular Diagnostics & Experimental Therapeutics, Beckman Research Institute of City of Hope, Duarte, USA

    3 shared publications
  • Long Gu

    Department of Molecular Diagnostics & Experimental Therapeutics, Beckman Research Institute of City of Hope, Duarte, USA

    3 shared publications
  • Amanda Blackmon

    Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, USA

    2 shared publications

Latest Publications

  • PCNA Macromolecular Complexes: PCNA Serves as a Molecular Hub Regulating Multiple Cellular Processes Inside and Outside of the Nucleus

    by Hamsini Kala, Dana Abou Abbas, Linda H. Malkas, Robert J. Hickey

    With over 27,100 papers currently written about Proliferating Cell Nuclear Antigen (PCNA) and more than 11,700 papers describing a role for the protein and its relationship to cancer, this chapter will just touch upon some of the important role’s PCNA has within cells and what types of proteins might interact with PCNA. This chapter is not meant to provide a thorough review of the multitude of protein complexes utilizing PCNA as a cofactor but rather highlight only some of those direct or indirect interactions between PCNA and its binding partners which together are involved in maintaining the genome, regulating cytoplasmic activities, and participating in immune surveillance. Additionally, this chapter will provide a high-level overview of how the caPCNA isoform is being used as a platform for a new class of anticancer therapeutic agent that selectively kills cancer cells, while leaving non-cancer cells unharmed.

  • Open Access

    Correction: AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibition

    by HyunJun Kang, Melissa Valerio, Jia Feng, Long Gu, Dinh Hoa Hoang, Amanda Blackmon, Shawn Sharkas, Khyatiben Pathak, Jennifer Jossart, Zhuo Li, et al.

  • Open Access

    AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibition

    by HyunJun Kang, Melissa Valerio, Jia Feng, Long Gu, Dinh Hoa Hoang, Amanda Blackmon, Shawn Sharkas, Khyatiben Pathak, Jennifer Jossart, Zhuo Li, et al.

    Cytoplasmic proliferating cell nuclear antigen (PCNA) is highly expressed in acute myeloid leukemia (AML) cells, supporting oxidative metabolism and leukemia stem cell (LSC) growth. We report on AOH1996 (AOH), an oral compound targeting cancer-associated PCNA, which shows significant antileukemic activity. AOH inhibited growth in AML cell lines and primary CD34 + CD38 − blasts (LSC-enriched) in vitro while sparing normal hematopoietic stem cells (HSCs). In vivo, AOH-treated mice demonstrated prolonged survival compared to controls (50 vs. 35 days; p < 0.0001) with reduced LSC burden, as shown in secondary transplants (42 vs. 30 days, p < 0.0001). Mechanistically, AOH disrupted mitochondrial PCNA’s binding to the OPA1 protein, enhancing OPA1’s interaction with its E3 ligase, MARCH5, which led to OPA1 degradation. This process reduced mitochondrial length, fatty acid oxidation (FAO), and oxidative phosphorylation (OXPHOS), thereby inhibiting LSC expansion. The addition of venetoclax (VEN), an FDA-approved Bcl-2 inhibitor, further enhanced AOH’s effects, reducing mitochondrial length, FAO, and OXPHOS while improving survival in AML models. While VEN is approved for AML, AOH is under clinical investigation for solid tumors, and our findings support its broader therapeutic potential.


  • Open Access

    Small molecule targeting of transcription-replication conflict for selective chemotherapy

    by Long Gu, Min Li, Caroline M. Li, Pouya Haratipour, Robert Lingeman, Jennifer Jossart, Margarita Gutova, Linda Flores, Caitlyn Hyde, Nikola Kenjić, et al.


  • Open Access

    Therapeutic Targeting of DNA Replication Stress in Cancer

    by Long Gu, Robert J. Hickey, Linda H. Malkas

    This article reviews the currently used therapeutic strategies to target DNA replication stress for cancer treatment in the clinic, highlighting their effectiveness and limitations due to toxicity and drug resistance. Cancer cells experience enhanced spontaneous DNA damage due to compromised DNA replication machinery, elevated levels of reactive oxygen species, loss of tumor suppressor genes, and/or constitutive activation of oncogenes. Consequently, these cells are addicted to DNA damage response signaling pathways and repair machinery to maintain genome stability and support survival and proliferation. Chemotherapeutic drugs exploit this genetic instability by inducing additional DNA damage to overwhelm the repair system in cancer cells. However, the clinical use of DNA-damaging agents is limited by their toxicity and drug resistance often arises. To address these issues, the article discusses a potential strategy to target the cancer-associated isoform of proliferating cell nuclear antigen (caPCNA), which plays a central role in the DNA replication and damage response network. Small molecule and peptide agents that specifically target caPCNA can selectively target cancer cells without significant toxicity to normal cells or experimental animals.


  • Open Access

    Novel Peptide Therapeutic Approaches for Cancer Treatment

    by Caroline M. Li, Pouya Haratipour, Robert G. Lingeman, J. Jefferson P. Perry, Long Gu, Robert J. Hickey, Linda H. Malkas

    Peptides are increasingly being developed for use as therapeutics to treat many ailments, including cancer. Therapeutic peptides have the advantages of target specificity and low toxicity. The anticancer effects of a peptide can be the direct result of the peptide binding its intended target, or the peptide may be conjugated to a chemotherapy drug or radionuclide and used to target the agent to cancer cells. Peptides can be targeted to proteins on the cell surface, where the peptide–protein interaction can initiate internalization of the complex, or the peptide can be designed to directly cross the cell membrane. Peptides can induce cell death by numerous mechanisms including membrane disruption and subsequent necrosis, apoptosis, tumor angiogenesis inhibition, immune regulation, disruption of cell signaling pathways, cell cycle regulation, DNA repair pathways, or cell death pathways. Although using peptides as therapeutics has many advantages, peptides have the disadvantage of being easily degraded by proteases once administered and, depending on the mode of administration, often have difficulty being adsorbed into the blood stream. In this review, we discuss strategies recently developed to overcome these obstacles of peptide delivery and bioavailability. In addition, we present many examples of peptides developed to fight cancer.


  • Open Access

    Validating the disruption of proliferating cell nuclear antigen interactions in the development of targeted cancer therapeutics

    by Shanna J. Smith, Robert J. Hickey, Linda H. Malkas

    Human DNA replication and repair is a highly coordinated process involving the specifically timed actions of numerous proteins and enzymes. Many of these proteins require interaction with proliferating cell nuclear antigen (PCNA) for activation within the process. The interdomain connector loop (IDCL) of PCNA provides a docking site for many of those proteins, suggesting that this region is critically important in the regulation of cellular function. Previous work in this laboratory has demonstrated that a peptide mimicking a specific region of the IDCL (caPeptide) has the ability to disrupt key protein-protein interactions between PCNA and its binding partners, thereby inhibiting DNA replication within the cells. In this study, we confirm the ability of the caPeptide to disrupt DNA replication function using both intact cell and in vitro DNA replication assays. Further, we were able to demonstrate that treatment with caPeptide results in a decrease of polymerase δ activity that correlates with the observed decrease in DNA replication. We have also successfully developed a surface plasmon resonance (SPR) assay to validate the disruption of the PCNA-pol δ interaction with caPeptide.


  • Open Access

    A Peptide Mimicking a Region in Proliferating Cell Nuclear Antigen Specific to Key Protein Interactions Is Cytotoxic to Breast Cancer

    by Shanna J. Smith, Long Gu, Elizabeth A. Phipps, Lacey E. Dobrolecki, Karla S. Mabrey, Pattie Gulley, Kelsey L. Dillehay, Zhongyun Dong, Gregg B. Fields, Yun-Ru Chen, et al.

    Proliferating cell nuclear antigen (PCNA) is a highly conserved protein necessary for proper component loading during the DNA replication and repair process. Proteins make a connection within the interdomain connector loop of PCNA, and much of the regulation is a result of the inherent competition for this docking site. If this target region of PCNA is modified, the DNA replication and repair process in cancer cells is potentially altered. Exploitation of this cancer-associated region has implications for targeted breast cancer therapy. In the present communication, we characterize a novel peptide (caPeptide) that has been synthesized to mimic the sequence identified as critical to the cancer-associated isoform of PCNA. This peptide is delivered into cells using a nine-arginine linking mechanism, and the resulting peptide (R9-cc-caPeptide) exhibits cytotoxicity in a triple-negative breast cancer cell line, MDA-MB-436, while having less of an effect on the normal counterparts (MCF10A and primary breast epithelial cells). The novel peptide was then evaluated for cytotoxicity using various in vivo techniques, including ATP activity assays, flow cytometry, and clonogenetic assays. This cytotoxicity has been observed in other breast cancer cell lines (MCF7 and HCC1937) and other forms of cancer (pancreatic and lymphoma). R9-cc-caPeptide has also been shown to block the association of PCNA with chromatin. Alanine scanning of the peptide sequence, combined with preliminary in silico modeling, gives insight to the disruptive ability and the molecular mechanism of action of the therapeutic peptide in vivo.


  • Open Access

    Error-promoting DNA synthesis in ovarian cancer cells

    by Heqiao Dai, Robert J. Hickey, Jianying Liu, Robert M. Bigsby, Carita Lanner, Linda H. Malkas


  • Open Access

    Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration

    by Amos H. P. Loh, Rachel C. Brennan, Walter H. Lang, Robert J. Hickey, Linda H. Malkas, John A. Sandoval

    Children with solid tumors represent a unique population. Recent improvements in pediatric solid tumor survival rates have been confined to low- and moderate-risk cancers, whereas minimal to no notable improvement in survival have been observed in high-risk and advanced-stage childhood tumors. The development of novel therapeutic agents likely holds the key for patients with advanced disease that are frequently plagued with treatment failure and relapse. In the last years, biological advances have allowed for improved molecular characterization of signaling molecules and pathways contributing to tumor formation and growth. Exploiting these oncogenic cascades holds the promise for development of therapies that target alterations unique to an individual child’s tumor. An emerging target includes the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, which is activated in many adult solid cancers. Antagonists targeting this pathway have the potential to inhibit multiple key nodes and the use of selected rational combinations of these PI3K/Akt/mTOR inhibitors may be required to achieve the maximal cytotoxic response. Here, we examine the role of the PI3K/AKT/mTOR axis in selected pediatric solid tumors, review the pathway specific agents currently in clinical trials, and explore the ongoing challenges of the inhibition of this pathway in the clinical development of these agents in children.